The Influence of Different At-home Exercise Strategies on 24h Glycemic Control

May 12, 2023 updated by: Jenna Gillen, University of Toronto

The Influence of Different At-home Exercise Strategies on 24h Glycemic Control in Women at Risk for With Metabolic Disease

This study will determine how different at-home exercise strategies influence 24hr glycemic control in women with metabolic dysfunction.

Study Overview

Detailed Description

Elevations in blood glucose concentration increase risk for cardiometabolic diseases including type 2 diabetes and cardiovascular diseases. Exercise can improve glycemic control, but there is limited research comparing the effectiveness of different exercise strategies in women. The aim of this study is to examine, under free-living conditions, how performing either walking and bodyweight interval exercise after dinner influences glycemic control in women with or at risk for type 2 diabetes. Glycemic control will be measured with continuous glucose monitors.

Study Type

Interventional

Enrollment (Actual)

107

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Ontario
      • Toronto, Ontario, Canada, M5S1A1
        • University of Toronto

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

50 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

Yes

Description

Inclusion Criteria:

  • Females
  • no cancer history
  • ≥50 years old
  • Have metabolic dysfunction (defined as self-reported diagnosis of pre-diabetes, type 2 diabetes, or at least moderate Canadian diabetes risk (CANRISK) score)
  • Owns a smartphone with Bluetooth capability with Apple or Android operating system
  • deemed safe to exercise as per the CSEP Get Active Questionnaire
  • Enrolled in NCT05454943

Exclusion Criteria:

  • Type 1 diabetes
  • Taking exogenous insulin, sulfonylureas, or GLP-1 receptor agonists
  • Self-reported history of an eating disorder
  • BMI <18.5 kg/m
  • Working night or rotating shifts
  • Eating window <12 hours or consistently eating less than 3 meals/day in the past 3 months
  • Major dietary changes within the past 3 months (i.e. calorie counting, ketogenic diet)

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Crossover Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Bodyweight interval exercise
Performing 15 minutes of bodyweight interval exercise after dinner
Performing 15 minutes of bodyweight interval exercise after dinner at home by following a video
Experimental: Walking
Performing a 30 minute walk after dinner
Performing a 30 minute minute walk after dinner at home
No Intervention: Non exercise control
Performing no exercise after dinner

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
24hr Glucose area under the curve
Time Frame: 24 hours
Glucose area under the curve over 24hr
24 hours

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
24hr Average glucose concentration
Time Frame: 24 hours
Average glucose concentration over 24 hr
24 hours
Postprandial dinner glucose response
Time Frame: 2 hours
Measured as the 2hr postprandial glucose incremental area under the curve (iAUC), average glucose and peak glucose
2 hours
Postprandial breakfast glucose response
Time Frame: 2 hours
Measured as the 2hr postprandial iAUC, average glucose and peak glucose
2 hours
Postprandial lunch glucose response
Time Frame: 2 hours
Measured as the 2hr postprandial glucose iAUC, average glucose and peak glucose
2 hours
Nocturnal glucose
Time Frame: ~6-8 hours
Measured as the overnight glucose average and AUC
~6-8 hours
Time in hyperglycemia
Time Frame: 24 hours
Time (minutes and percent per day) above 10mmol/L over 24hr
24 hours
Time in hypoglycemia
Time Frame: 24 hours
Time (minutes and percent per day) under 3.9mmol/L over 24 hr
24 hours
Time in range
Time Frame: 24 hours
Time (minutes and percent per day) above 3.9 but under 10mmol/L
24 hours
Continuous overall net glycemic action (CONGA)
Time Frame: 24 hours
Calculated measure of glycemic variability
24 hours
Change in glucose during exercise
Time Frame: 15-30 minutes
Post vs. pre glucose concentration around exercise
15-30 minutes
Mean amplitude glycemic excursion (MAGE)
Time Frame: 24 hours
Calculated measure of glycemic variability
24 hours
Standard deviation (SD)
Time Frame: 24 hours
Calculated measure of glycemic variability
24 hours
% coefficient of variation (CV)
Time Frame: 24 hours
Calculated measure of glycemic variability
24 hours

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Jenna Gillen, PhD, University of Toronto

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

July 7, 2022

Primary Completion (Actual)

April 30, 2023

Study Completion (Actual)

April 30, 2023

Study Registration Dates

First Submitted

July 29, 2022

First Submitted That Met QC Criteria

August 4, 2022

First Posted (Actual)

August 8, 2022

Study Record Updates

Last Update Posted (Actual)

May 15, 2023

Last Update Submitted That Met QC Criteria

May 12, 2023

Last Verified

May 1, 2023

More Information

Terms related to this study

Other Study ID Numbers

  • 42756-2

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Metabolic Disturbance

Clinical Trials on Bodyweight interval exercise

Subscribe